Spots Global Cancer Trial Database for inavolisib
Every month we try and update this database with for inavolisib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer | NCT04191499 | Breast Cancer | Inavolisib Placebo Palbociclib Fulvestrant | 18 Years - | Hoffmann-La Roche | |
| Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer | NCT05306041 | HER2-positive B... | Inavolisib PHESGO Endocrine thera... | 18 Years - | German Breast Group | |
| A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response | NCT04632992 | Advanced Unrese... | Entrectinib Inavolisib Alectinib Ipatasertib Atezolizumab Trastuzumab Emt... Pertuzumab, Tra... Tucatinib Investigator's ... Paclitaxel Tiragolumab Pralsetinib | 18 Years - | Genentech, Inc. | |
| A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer | NCT04486352 | Endometrial Can... | Atezolizumab - ... Bevacizumab Ipatasertib Talazoparib Trastuzumab emt... Tiragolumab Atezolizumab - ... Inavolisib Letrozole Giredestrant Abemaciclib | 18 Years - | Alliance Foundation Trials, LLC. | |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | NCT04802759 | Inoperable, Loc... | Giredestrant Abemaciclib Ipatasertib Inavolisib Ribociclib Everolimus Samuraciclib PH FDC SC Palbociclib Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer | NCT03006172 | Breast Cancer Solid Tumor | Inavolisib Fulvestrant Letrozole Palbociclib Metformin Trastuzumab Pertuzumab | 18 Years - | Genentech, Inc. | |
| A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | NCT05894239 | Metastatic Brea... | Inavolisib Phesgo Placebo Taxane-based Ch... Optional Endocr... | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | NCT03424005 | Breast Cancer | Capecitabine Atezolizumab Ipatasertib SGN-LIV1A Bevacizumab Chemotherapy (G... Selicrelumab Tocilizumab Nab-Paclitaxel Sacituzumab Gov... Abemaciclib Fulvestrant Ribociclib Inavolisib Inavolisib (9 m... Inavolisib (6 m... Trastuzumab Der... | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | NCT04931342 | Ovarian Cancer | Ipatasertib Cobimetinib Trastuzumab Emt... Atezolizumab Bevacizumab Paclitaxel Giredestrant Abemaciclib Inavolisib Palbociclib Letrozole Olaparib Luteinizing Hor... Cyclophosphamid... Inavolisib | 18 Years - | Hoffmann-La Roche | |
| Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | NCT04589845 | Solid Tumors | Entrectinib Entrectinib Alectinib Atezolizumab Ipatasertib Trastuzumab emt... Idasanutlin Inavolisib Belvarafenib Pralsetinib GDC-6036 Camonsertib | - | Hoffmann-La Roche | |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | NCT03424005 | Breast Cancer | Capecitabine Atezolizumab Ipatasertib SGN-LIV1A Bevacizumab Chemotherapy (G... Selicrelumab Tocilizumab Nab-Paclitaxel Sacituzumab Gov... Abemaciclib Fulvestrant Ribociclib Inavolisib Inavolisib (9 m... Inavolisib (6 m... Trastuzumab Der... | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | NCT04802759 | Inoperable, Loc... | Giredestrant Abemaciclib Ipatasertib Inavolisib Ribociclib Everolimus Samuraciclib PH FDC SC Palbociclib Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response | NCT04632992 | Advanced Unrese... | Entrectinib Inavolisib Alectinib Ipatasertib Atezolizumab Trastuzumab Emt... Pertuzumab, Tra... Tucatinib Investigator's ... Paclitaxel Tiragolumab Pralsetinib | 18 Years - | Genentech, Inc. | |
| A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy | NCT05646862 | Breast Cancer | Inavolisib Fulvestrant Alpelisib | 18 Years - | Hoffmann-La Roche | |
| Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | NCT04589845 | Solid Tumors | Entrectinib Entrectinib Alectinib Atezolizumab Ipatasertib Trastuzumab emt... Idasanutlin Inavolisib Belvarafenib Pralsetinib GDC-6036 Camonsertib | - | Hoffmann-La Roche | |
| CRAFT: The NCT-PMO-1602 Phase II Trial | NCT04551521 | Metastatic or L... | Vemurafenib Cobimetinib Atezolizumab Trastuzumab Pertuzumab Alectinib Ipatasertib Atezolizumab Atezolizumab Atezolizumab Inavolisib | 18 Years - | German Cancer Research Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
